Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID-19: Derivation and Validation of the HA 2 T 2 COVID-19 Mortality Risk Score

Background The independent prognostic value of troponin and other biomarker elevation among patients with coronavirus disease 2019 (COVID-19) are unclear. We sought to characterize biomarker levels in patients hospitalized with COVID-19 and develop and validate a mortality risk score. Methods and Re...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2021-03, Vol.10 (6), p.e018477
Main Authors: Manocha, Kevin K, Kirzner, Jared, Ying, Xiaohan, Yeo, Ilhwan, Peltzer, Bradley, Ang, Bryan, Li, Han A, Lerman, Bruce B, Safford, Monika M, Goyal, Parag, Cheung, Jim W
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biomarkers - blood
C-Reactive Protein - analysis
Cardiovascular Diseases - blood
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - mortality
COVID-19 - blood
COVID-19 - diagnosis
COVID-19 - mortality
Female
Ferritins - blood
Fibrin Fibrinogen Degradation Products - analysis
Health Status Indicators
Hospital Mortality
Hospitalization
Humans
Male
Middle Aged
Natriuretic Peptide, Brain - blood
Predictive Value of Tests
Prognosis
Reproducibility of Results
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Troponin I - blood
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The independent prognostic value of troponin and other biomarker elevation among patients with coronavirus disease 2019 (COVID-19) are unclear. We sought to characterize biomarker levels in patients hospitalized with COVID-19 and develop and validate a mortality risk score. Methods and Results An observational cohort study of 1053 patients with COVID-19 was conducted. Patients with all of the following biomarkers measured-troponin-I, B-type natriuretic peptide, C-reactive protein, ferritin, and d-dimer (n=446) -were identified. Maximum levels for each biomarker were recorded. The primary end point was 30-day in-hospital mortality. Multivariable logistic regression was used to construct a mortality risk score. Validation of the risk score was performed using an independent patient cohort (n=440). Mean age of patients was 65.0±15.2 years and 65.3% were men. Overall, 444 (99.6%) had elevation of any biomarker. Among tested biomarkers, troponin-I ≥0.34 ng/mL was the only independent predictor of 30-day mortality (adjusted odds ratio, 4.38;
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.120.018477